title: Sitagliptin-induced hemolysis.
abstract: Sitagliptin is a newer oral hypoglycemic drug of the dipeptidyl peptidase-IV inhibitor class. It appears to be a promising newer oral hypoglycemic agent. The advantages are the absence of hypoglycemia when used as monotherapy and they cause less gain weight. We report a case of sitagliptin-induced hemolysis, a rare side effect, not reported in the literature. As sitagliptin is widely used in type 2 diabetes mellitus physicians should be aware of the possibility of this rare but potentially serious adverse drug reaction.
authors.affiliation: Department of Medicine, Kasturba Medical College, Manipal University, Manipal, India.
authors.forename: Ragini
authors.initials: R
authors.lastname: Bekur
authors.forename: M V
authors.initials: MV
authors.lastname: Nagaraja
authors.forename: K N
authors.initials: KN
authors.lastname: Shivashankara
authors.forename: Weena
authors.initials: W
authors.lastname: Stanley